In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.
Age range 18 to 65 years old.
Capacity to consent (able to read, understand, and sign informed consent).
Age range 18 to 65 years old.
Capacity to consent (able to read, understand, and sign informed consent).
Nicotine use, including tobacco, e-cigarettes, nicotine patch, nicotine gum, within the past year [except for occasional users, who cannot use nicotine products in the week before the scan].
Need for use of medication during the study that will affect cholinergic levels.
Problematic drug/alcohol use that is judged sufficient to interfere with study procedures during the treatment period or impact participant safety.
Significant active physical illness or neurological deficit that may affect brain function or imaging.
Stony Brook University
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Mental Health (NIMH)
Collaborator